Tenaya Therapeutics, Inc. released a slide deck on May 17, 2026, covering results from its RIDGE-1 Phase Ib/II trial of TN-401 gene therapy. The presentation focuses on treatment for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
The slide deck was issued by the company in connection with the clinical data review. It provides details on the ongoing study of the gene therapy candidate under the ticker TNYA on NASDAQ. No additional outcomes or participant numbers were specified in the release materials.
